Yingke Private Equity
PE-backed Adlai Nortye pursues US listing
Adlai Nortye, a private equity-backed Chinese cancer drug developer that previously filed to list in Hong Kong, is now targeting an IPO in the US.
CPE leads $150m Series B for China CDMO
Joinn Biologics, a China-based contract development and manufacturing organization (CDMO), has raised $150 million in Series B funding led by CPE.
Hong Kong sees rush of VC-backed biotech IPO filings
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
China online pharmacy Dingdang seeks Hong Kong IPO
Dingdang Health, a Chinese online pharmacy business that raised $220 million in funding earlier this month, has filed for a Hong Kong IPO.
TPG leads $220m round for China's Dingdang Health
TPG Capital has led a $220 million round for Chinese online pharmacy services provider Dingdang Health.
China's Yingke closes renminbi, US dollar funds
Shanghai-based Yingke Private Equity has raised RMB10 billion ($1.57 billion) for its latest renminbi-denominated fund as well as an undisclosed sum for a third US dollar vehicle.
China's Yingke raises $1.5b technology, healthcare fund
Shanghai-based Yingke Private Equity has raised RMB10 billion ($1.5 billion) for a fund that will focus on core technology and biomedical science assets in China.